COLUMBIA, MD and TORONTO--(Marketwire - October 09, 2012) -
Medifocus Inc. (OTCQX: MDFZF
) (TSX VENTURE: MFS
) is pleased to announce that it has retained Consulting for Strategic Growth ("CFSG1") as its U.S. investor and public relations counsel. Robert Giordano and his team of experts will begin to implement an investor and public relations program focused on building investor and media awareness of Medifocus' growing market position within the biotechnology industry as it further develops its patented portfolio of microwave-focusing technology while driving continued sales from its newly acquired technology, Prolieve®.
Mr. Giordano stated, "We are extremely excited to begin sharing the Medifocus story at such a monumental point of the Company's growth." He continued, "In the past several months, Medifocus has transformed itself to a mature, revenue-generating business through the acquisition of Prolieve®, an FDA-approved device for the treatment of Benign Prostatic Hyperplasia (BPH). With a building opportunity to market Prolieve® around the world and, now, the near-term clinical advancement of the Company's patented adaptive phased array (APA) microwave focusing technology platform to treat breast cancer, tremendous growth opportunity lies ahead."
Medifocus acquired Prolieve® from Boston Scientific Corporation in July 2012, adding over 50 new patents to the Company's already strong patent portfolio. The Company is simultaneously driving increased sales of Prolieve® while bringing its APA-focused heat platform through its Phase III clinical trials.
Medifocus owns a patented microwave focusing technology platform (the Adaptive Phased Array ("APA") technology), which can precisely target and control microwave energy to cause heating in cancerous tumors anywhere in the body reliably and repeatedly. The ability to target tumors with a precision controlled dose of heat can be used to destroy tumors at higher temperatures, to treat tumors in combination with chemotherapy and/or radiation at moderate temperatures for increased effectiveness and reduced toxicity and to trigger the targeted release of therapeutic drugs and genes at tumor sites at lower temperatures. While the core technology has been licensed from the Massachusetts Institute of Technology, Medifocus has further refined the precision of the microwave focusing and control ability and developed a commercial system dedicated exclusively for the treatment of Breast Cancer. With the acquisition of Prolieve, Medifocus now owns in addition, a revenue generating commercial BPH heat treatment product generating cash flow to support the development and commercialization of other catheter based or APA based external focused heat systems for targeted thermotherapy of deep seated tumors anywhere in the body. Please visit www.medifocusinc.com for more details.
Forward-Looking Statements and Information
This news release contains forward-looking statements, which may not be based on historical facts. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by applicable securities laws, the Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.